脂质包裹的编码抗基孔肯雅病毒中和单克隆抗体mRNA的1期试验
这项1期首次人体随机安慰剂对照概念验证试验于2019年1月至2020年6月评估mRNA-1944的安全性及药理学,该药为脂质纳米颗粒包裹的编码基孔肯雅病毒(CHIKV)特异性单克隆中和抗体CHKV-24重链和轻链的mRNA。预设中期分析纳入38名健康受试者,单次静脉输注0.1、0.3、0.6 mg kg-1或每周两次0.3 mg kg-1。单次输注后12、24、48小时观察到剂量依赖性具有中和活性的CHKV-24 IgG水平,在0.3和0.6 mg kg-1剂量下持续≥16周(平均t1/2约69天);第二次0.3 mg kg-1剂量使CHKV-24 IgG水平增加1.8倍。不良事件为轻至中度,无严重不良事件。
要点
- mRNA-1944单次静脉输注后12、24、48小时产生剂量依赖性CHKV-24 IgG,滴度≥1 µg ml-1。
- 0.3和0.6 mg kg-1剂量下CHKV-24 IgG持续≥16周,平均t1/2约69天。
- 第二次0.3 mg kg-1剂量后CHKV-24 IgG水平增加1.8倍,不良事件轻至中度且无严重不良事件。
核心结论
- mRNA-1944是首个在临床试验中显示体内表达和可检测体外中和活性的mRNA编码单克隆抗体,可能为CHIKV感染提供治疗选择。
- 有必要进一步在临床试验中评估mRNA-1944治疗CHIKV感染的潜在用途。
研究设计与样本
- 1期、首次人体、随机、安慰剂对照、概念验证试验,于2019年1月至2020年6月进行(NCT03829384)。
- 评估mRNA-1944(脂质纳米颗粒包裹的编码CHIKV特异性单克隆中和抗体CHKV-24重链和轻链的mRNA)的安全性和药理学。
- 预设中期分析纳入38名18-50岁健康受试者,接受静脉单次剂量0.1、0.3和0.6 mg kg-1或每周两次0.3 mg kg-1的mRNA-1944或安慰剂。
- 主要结局为评估递增剂量mRNA-1944在健康受试者中的安全性和耐受性;次要目标包括mRNA编码的CHKV-24免疫球蛋白重链和轻链及可电离氨基酸脂质的药代动力学,以及通过血清CHKV-24 IgG、血浆可电离氨基酸脂质和血清CHKV-24 IgG浓度评估的药效学。
主要发现
- 单次输注后12、24、48小时观察到剂量依赖性具有中和活性的CHKV-24 IgG水平,滴度达到预测治疗相关浓度(≥1 µg ml-1)。
- 在0.3和0.6 mg kg-1剂量下CHKV-24 IgG持续≥16周(平均t1/2约69天)。
- 首次给药后1周给予第二次0.3 mg kg-1剂量使CHKV-24 IgG水平增加1.8倍。
- 不良事件为轻至中度,第二次mRNA-1944剂量未使不良事件加重,无严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chikungunya virus (CHIKV) infection causes acute disease characterized by fever, rash and arthralgia, which progresses to severe and chronic arthritis in up to 50% of patients. Moreover, CHIKV infection can be fatal in infants or immunocompromised individuals and has no approved therapy or prevention. This phase 1, first-in-human, randomized, placebo-controlled, proof-of-concept trial conducted from January 2019 to June 2020 evaluated the safety and pharmacology of mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24 ( NCT03829384 ). The primary outcome was to evaluate the safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion in healthy participants aged 18-50 years. The secondary objectives included determination of the pharmacokinetics of mRNA encoding for CHKV-24 immunoglobulin heavy and light chains and ionizable amino lipid component and the pharmacodynamics of mRNA-1944 as assessed by serum concentrations of mRNA encoding for CHKV-24 immunoglobulin G (IgG), plasma concentrations of ionizable amino lipid and serum concentrations of CHKV-24 IgG. Here we report the results of a prespecified interim analysis of 38 healthy participants who received intravenous single doses of mRNA-1944 or placebo at 0.1, 0.3 and 0.6 mg kg-1, or two weekly doses at 0.3 mg kg-1. At 12, 24 and 48 h after single infusions, dose-dependent levels of CHKV-24 IgG with neutralizing activity were observed at titers predicted to be therapeutically relevant concentrations (≥1 µg ml-1) across doses that persisted for ≥16 weeks at 0.3 and 0.6 mg kg-1 (mean t1/2 approximately 69 d). A second 0.3 mg kg-1 dose 1 week after the first increased CHKV-24 IgG levels 1.8-fold. Adverse effects were mild to moderate in severity, did not worsen with a second mRNA-1944 dose and none were serious. To our knowledge, mRNA-1944 is the first mRNA-encoded monoclonal antibody showing in vivo expression and detectable ex vivo neutralizing activity in a clinical trial and may offer a treatment option for CHIKV infection. Further evaluation of the potential therapeutic use of mRNA-1944 in clinical trials for the treatment of CHIKV infection is warranted.
引用
- August A, Attarwala HZ, Himansu S, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021. PMID: 34887572. doi:10.1038/s41591-021-01573-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。